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Abstract
Background & Aims—Minocycline hepatotoxicity can present with prominent autoimmune 
features in previously healthy individuals. The aim of this study was to identify genetic 
determinants of minocycline DILI in a well-phenotyped cohort of patients.
Methods—Caucasian patients with minocycline DILI underwent genome-wide genotyping and 
were compared to unexposed population controls. Human leukocyte antigen (HLA) binding of 
minocycline was assessed using AutoDock Vina.
Results—Amongst the 25 cases, 80% were female, median age was 19 years and median latency 
from drug start to DILI onset was 318 days. At presentation, 76% had acute hepatocellular liver 
injury, median ALT 1077 U/L (range: 63 to 2333), median bilirubin 4.5 mg/dl (range: 0.2 to 16.7), 
and 90% had a +ANA. During follow-up, 50% were treated with corticosteroids and no subjects 
died or required a liver transplant. A significant association was noted between HLA-B*35:02 and 
risk for minocycline-DILI; a 16% carrier frequency in DILI cases compared to 0.6% in population 
controls (Odds Ratio: 29.6, 95% CI: 7.8-89.8, p=2.5 × 10-8). Verification of HLA-B*35:02 
imputation was confirmed by sequence-based HLA typing. HLA-B*35:02 carriers had similar 
presenting features and outcomes compared to non-carriers. In silico modeling studies support the 
hypothesis that direct binding of minocycline to this novel HLA risk allele might be an important 
initiating event in minocycline-DILI.
Conclusion—HLA-B*35:02 is a rare HLA allele that was more frequently identified in the 25 
minocycline-DILI cases compared to population controls. If confirmed in other cohorts, this HLA 
allele may prove to be a useful diagnostic marker of minocycline DILI.
Keywords
Drug induced liver injury; single nucleotide polymorphism; genetic association; autoimmunity; 
human leukocyte antigen
Idiosyncratic drug induced liver injury (DILI) is an important cause of acute and chronic 
liver injury in western patients. In addition to being a leading reason for regulatory actions 
amongst drugs in development and in the marketplace, DILI also accounts for 13% of adults 
with acute liver failure (1). A recent population based study indicated that the annual 
incidence of DILI was 19.1 per 100,000 person years in Iceland and that antibiotics were the 
most commonly implicated agents (2). Similarly, analyses from the ongoing Drug induced 
Liver Injury Network (DILIN) prospective study in the United States also identified 
antibiotics as the leading cause of DILI, with amoxicillin-clavulanate being most frequently 
implicated (3). Prior reports have also implicated minocycline as a cause of DILI with 
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characteristic clinical features including systemic arthralgias and detectable autoantibodies 
arising in young women (4). Recent studies have suggested that various laboratory, 
histological and clinical features can help differentiate auto-immune like DILI from sporadic 
autoimmune hepatitis but confirmatory studies are needed (4).
Several groups have begun studies to better define the presenting features, risk factors, and 
outcomes of patients with DILI. In addition to identifying improved causality assessment 
methods and DILI biomarkers, studies exploring the potential genetic susceptibility in these 
rare patients with DILI have been undertaken. Prior genome wide association studies 
(GWAS) have identified single nucleotide polymorphisms in the Human Leukocyte Antigen 
(HLA) locus that are associated with DILI susceptibility to several drugs (5-8). The aim of 
the current study is to report upon the presenting clinical features and outcomes of patients 
with DILI attributed to minocycline that have enrolled into the ongoing DILIN prospective 
and retrospective studies. In addition to exploring clinical phenotypes, we also set out to 
identify potential genetic susceptibility factors in patients with minocycline DILI compared 
to population controls, using GWAS and confirmatory sequence-based HLA typing. Finally, 
preliminary results exploring the potential mechanism of the HLA-B*35:02 association with 
minocycline DILI using in silico modelling are presented.
Methods
DILIN Prospective study
Most of the subjects were enrolled in the DILIN prospective study protocol. DILI onset was 
defined as the first date after a subject taking minocycline met the predefined laboratory 
criteria for study entry, of either a serum aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) level that exceeded 5 × the upper limit of normal (ULN) (or 5 × 
pretreatment baseline if baseline abnormal), a serum alkaline phosphatase (Alk P) that 
exceeded 2 × the ULN (or 2 × pretreatment baseline if baseline abnormal), a total bilirubin > 
2.5 mg/dl, or an international normalized ratio (INR) greater than 1.5 on two consecutive 
blood draws. All study participants were enrolled within 6 months of DILI onset.
A detailed medical history was obtained at the baseline study visit and additional laboratory 
and radiological testing were performed to more fully characterize the DILI event and 
exclude competing etiologies. Specifically, testing for hepatitis A, B, C, HIV, autoantibodies 
including anti-nuclear antibody titers, CMV, and EBV infection were obtained at the local 
laboratory. Enrolled patients were seen for a follow-up study visit at 6 months after initial 
enrollment and those with evidence of chronic DILI within 6 months of DILI onset were 
asked to return for additional follow-up visits at 12 and 24 months (9). Chronic DILI was 
defined as having a persistently elevated serum AST, ALT, or alk phos level, histological 
evidence of liver injury, or clinical evidence of portal hypertension at 6 months after DILI 
onset. Written informed consent was obtained from subjects and the study was approved by 
the Institutional Review Boards of all participating clinical sites.
The severity of the DILI episode was categorized on a 5-point scale from mild (1), moderate 
(2), moderate-hospitalized (3), severe (4), and fatal (5), where a fatal score was assigned 
only if the patient died or had liver transplant due to DILI (9). Of note, the clinical features 
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of some of the minocycline patients were previously presented in a separate report (10). In 
addition, clinical features from 2 of these cases have been posted as brief vignettes on the 
LiverTox website (see http://livertox.nlm.nih.gov/minocycline).
DILIN Retrospective study
DNA samples and phenotypic data from subjects with minocycline hepatotoxicity enrolled 
in the DILIN retrospective study were included. Study inclusion criteria were patients that 
developed DILI due to one of 8 prespecified drugs that included minocycline with a DILI 
onset date after 1994. Subjects had to have a total bilirubin of > 2.5 mg/dl and a complete set 
of labs at DILI onset, exclusion of competing causes, and outcome available for review. 
Retrospective study patients were either interviewed in person or over the phone to review 
the dose and duration of suspect medication use and facilitate collection of a DNA sample 
after obtaining written informed consent.
DILIGEN study
Only Caucasian subjects with DILI attributed to minocycline enrolled in the DILIGEN study 
with an available DNA sample were included. All subjects had (a) clinically apparent 
jaundice or bilirubin > 40 umol/L, or (b) a serum ALT > 5 × ULN or (c) Alk P > 2 × ULN 
plus any raised bilirubin above ULN (7). All patients had a Roussel Uclaf Causality 
Assessment Method (RUCAM) causality score of 3 or greater.
Liver histopathology
Available liver biopsies were reviewed by a single expert liver histopathologist (DEK). All 
samples were scored for multiple histological features as well as an overall pattern of liver 
injury (11).
Causality assessment
The causal relationship between the liver injury episode and the minocycline use were 
evaluated in a standardized fashion by the DILIN causality committee (12). A DILIN expert 
opinion causality score varying from 1 (Definite > 95% likelihood), 2 (Highly Likely 
75%-95% likelihood), 3 (Probable 50%-74% likelihood), 4 (Possible 25%-49% likelihood) 
to 5 (unlikely < 25% likelihood) was assigned by consensus agreement of committee 
members for all of the retrospective and prospective DILIN cases. In addition, a RUCAM 
score was calculated for each case and implicated agent (13). In subjects with 2 or more 
implicated drugs, an overall causality score was assigned to the case and then an individual 
causality score for each drug was given.
Controls
Since DILI has a very low prevalence and minocycline is widely prescribed in healthy 
individuals with an estimated 4.2 million prescriptions of tetracylines per year in the US, 
unselected population samples were used as study controls (14). We selected 10,588 
Caucasian controls from different available sources; the Welcome Trust Case Control 
Consortium (WTCCC) (http://www.wtccc.org.uk), the population reference sample 
(POPRES)and PGX4000118 and Spanish Bladder cancer cohort from dbGAP 
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(phs000346.v1). Since all cases of minocycline DILI were determined to be of primarily 
Northern European ancestry, the set of ancestry-matched controls totaled 6,835 individuals. 
Since prior medication exposure history was not available for the controls, we presume that 
none of these patients previously received minocycline.
Genome-wide SNP and HLA analysis
Genome-wide genotyping of DILI cases was performed by the Broad Institute in Boston by 
Illumina Infinium HumanCoreExome BeadChip (n=19) or at the Duke Center for Human 
Genome Variation on the Illumina 1Mduo array (n=6). A total of 505,740 markers shared 
across the different genotyping platforms used for DILI cases and controls passed quality 
control (QC) and no samples were excluded for low quality profile.
For each cohort, single nucleotide polymorphisms (SNPs) with poor quality data were 
pruned before the imputation to avoid false positives. The imputation was performed by 
batches dividing the cohorts by the genotyping platform used. For each batch, we first 
phased the data by SHAPEIT (version v2.r727)(15), to increase the accuracy of the 
imputation. Then, imputation was carried out using IMPUTE2 (version 3) with the 1000 
Genomes Project (release v321) dataset as the reference panel (16). We used an ethnically 
mixed panel to improve the quality of the imputation for rare variants. We retained imputed 
genotypes with: (a) posterior probability > 0.9 in each genotyping batch, (b) no significant 
difference in missingness between cases and controls (χ2 test, p-value > 0.0001), (c) no 
significant deviation from Hardy-Weinberg equilibrium (p-value > 0.0001), (d) missing data 
not greater than 5% in each single genotyping batch, (e) info score greater than 0.8 in each 
genotyping batch. Since the imputation quality is higher for common variants, we selected 
SNPs with MAF in the 1000 Genomes Project greater or equal of 0.01. The imputed cohorts 
were then merged and genotyped SNPs were used to replace imputed SNP genotypes if 
previously eliminated during the build of the batch groups. For each imputed SNP, possible 
batch effects were detected by testing the association (by logistic regression) between 
controls within the same population typed by different platforms. SNPs with association p-
values less than 0.005 in this control comparison were excluded from the analysis. For each 
cohort, HLA alleles were also inferred using HIBAG (17) using the reference predictor 
panels specific for each genotyped chip. The top associated HLA type was further validated 
by sequence-based HLA typing at Histogenetics (Ossining, NY, USA). A proxy for HLA-
B*35:02, rs148631562, was typed with a TaqMan® SNP genotyping assay (ThermoFisher 
Scientific, Waltham, MA) in accordance with the manufacturer's recommendations in 7 
additional European ethnicity cases.
Statistical analysis
The effect of population structure was assessed through principal components analysis 
(PCA) using the smartPCA program from the EIGENSTRAT package (version 3.0) (18). 
The statistical association of each marker (HLA allele or SNP) with risk for minocycline 
DILI was determined by logistic regression with the first ten significant principal 
components as covariates under an additive genetic model. The lack of association between 
the HLA-B*35:02 allele and EIGENSTRAT axes can be seen in Figure S1. Association and 
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heterogeneity tests were carried out using PLINK (19). We set the genome-wide significance 
p-value threshold to 1.0 × 10-8 to correct for multiple testing. Given the high prior 
probability of HLA association with risk for DILI, an HLA-wide significance threshold was 
determined by Bonferroni correction for the 217 HLA alleles tested for association (p=2.3 × 
10-4). No test statistic inflation was observed for the results. To test for independent effects 
within regions having multiple associated variants, we included one or more variants as 
covariates and tested the residual effect of these variants after adjusting for the top 
associated allele. Differences in clinical characteristics among sample groups were tested by 
Fisher's Exact test or one-way ANOVA. All detailed analyses and Manhattan plots were 
performed with R (Version 3.0.2). Regional plots were drawn by LocusZoom (20).
HLA modelling and molecular docking
An atomic model of HLA-B*35:02 was generated by SWISS-MODEL (21) using the HLA-
B*35:02 sequence found in IMGT/HLA (22). The SMILES string of minocycline was 
obtained from PubChem and translated into 3 dimensional coordinates using the NCI/CADD 
translator (http://cactus.nci.nih.gov/translate/). AutoDock Tools was used to prepare files for 
molecular docking using AutoDock Vina (23). The top 9 scoring orientations were studied 
with the highest scoring pose shown in Figure 3.
Results
Patient population
A total of 25 Caucasian patients with DILI attributed to minocycline constitute our study 
population. Eighteen of the patients were enrolled in the DILIN prospective study, 4 were 
recruited in the DILIN retrospective study and 3 subjects were enrolled from DILIGEN. As 
shown in Table 1, the majority of subjects were female (80%) with a median age of 19 years 
(range: 16-61). Indications for minocycline use were dermatologic in 100%. At presentation, 
the majority of subjects had an acute hepatocellular pattern of liver injury with a median 
serum ALT of 1077 U/L, median Alk P of 176 U/L, and 52% of the subjects were jaundiced. 
The median duration of minocycline use was 55 weeks (range: < 1 to >122) with 52% 
having taken the drug for > 12 months. Hypersensitivity features at presentation included 
4% with eosinophilia, 32% with fever, and 20% with a rash. The majority of subjects had a 
+ ANA (90%) determined at their local hospital lab, 32% had detectable smooth muscle 
antibody, and 58% had hypergammaglobulinemia.
A liver biopsy was obtained during the process of clinical evaluation and available for 
central review in 8 subjects (Table 2). The time from DILI onset to liver biopsy varied from 
2 to 220 days with a median time of 73 days. The pattern of injury was acute (lobular 
predominant) hepatitis in 3 patients and chronic (portal predominant) hepatitis in 5 patients. 
In 2 of the cases of acute hepatitis and one of the cases of chronic hepatitis, there was mild 
to moderate zone 3 bile accumulation (cholestatic hepatitis). Half of the cases had marked 
interface hepatitis and in 2 cases, this was associated with bridging necrosis. Mild confluent 
necrosis was seen in 3 cases. Portal plasma cell infiltrates were prominent in 3 cases, while 
eosinophils were prominent in 5 cases. The 3 cases of cholestatic hepatitis all had prominent 
portal neutrophil infiltrates. On the basis of pattern and plasma cell infiltration only 3 cases 
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showed classic features that would suggest autoimmune hepatitis. Fibrosis was present as 
periportal expansion in most cases, but two cases had evidence of early bridging fibrosis.
During follow-up, none of the patients died or underwent liver transplantation. However, 5 
(28%) of the 18 DILIN prospective patients met pre-determined criteria for chronic DILI at 
6 months after injury onset. At 24 months of follow-up, all 5 patients had normalized their 
labs. Local physicians treated 12 subjects (50%) with corticosteroids. The median duration 
of steroid use was 160 days (range: 4 to 435 days) and 27% of the DILIN patients remained 
on steroids for at least 6 months after DILI onset.
Genetic association studies
A genome-wide association study was undertaken on the 25 minocycline DILI cases, 
including association testing of HLA alleles imputed from SNP genotype data in the major 
histocompatibility complex (MHC) region on chromosome 6. The results of the genome-
wide scan did not reveal any individual SNP or genomic region showing significant 
association with risk for minocycline-DILI after multiple test correction. However, when 
assessing the HLA types imputed from SNP genotype data in the MHC region, we observed 
a significant enrichment of the HLA-B*35:02 allele in the cases versus population controls 
(16% vs 0.6%, Odds ratio 29.6, 95% CI: 7.8-89.8, p = 2.5 × 10-8) (Table 3). The association 
with the imputed HLA-B*35:02 allele was then confirmed with sequence-based HLA typing 
(Figures 1 and 2).
HLA docking studies
Although the mechanistic basis for HLA associations with DILI is not known, it is presumed 
to involve: 1) direct binding of either the drug or a drug metabolite to HLA molecules or a 
metabolite-peptide adduct binding to HLA molecules, 2) effects on selection (expansion or 
deletion) of HLA restricted drug-specific T cells, and/or 3) indirect effects due to linked 
causative genes. To determine if minocycline has the potential to bind HLA-B*35:02, we 
used molecular docking to predict putative interactions. Although the structure of HLA-
B*35:02 has not been solved, it is sufficiently similar (98.9 %) to a solved crystal structure 
(HLA-B*35:01, PDB code 1XH3) allowing the generation of a high confidence model. The 
crystal structure of abacavir bound to HLA-B*57:01 provided a rational basis for prediction 
of sites within the antigen binding cleft that permit drug/HLA interactions (24, 25) . We used 
a high confidence model of HLA-B*35:02 and knowledge of drug/HLA contact sites to 
predict the likelihood of direct minocycline interactions with HLA-B*35:02. We used 
AutoDock Vina to dock minocycline into the antigen binding cleft of HLA-B*35:02 yielding 
a predicted interaction (estimated ΔG=-7.9 kcal per mole, compared to control docking of 
abacavir into HLA-B*57:01, ΔG=-7.2 kcal per mole (Figure 3). These data suggest that 
minocycline has the potential to bind the HLA-B*35:02 antigen binding cleft.
Discussion
Our study demonstrates a higher frequency of HLA-B*35:02 amongst the 25 patients with 
minocycline DILI compared to a large group of population controls. The GWAS results were 
confirmed using sequence-based HLA typing. Although further validation in an independent 
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and larger group of patients with minocycline DILI are needed, the results are in line with 
previous genetic studies of DILI showing (often drug-specific) risk factors in both HLA 
Class I and HLA Class II genes (5,6). HLA-B*35:02 has a low frequency in the general 
population, with an allele frequency of only 0.3% in Caucasians and less than 0.1% in 
African Americans.
A review of the literature demonstrates that HLA-* 35:02 is moderately associated with the 
rate of HIV progression to AIDS in Caucasian patients (26). It remains possible that 
HLA*B-35:02 could be a marker for the underlying condition of facial acne for which 
minocycline was prescribed. However, prior GWAS in patients with acne has failed to 
demonstrate this association (27-29). Furthermore, our molecular docking data suggest that 
minocycline is capable of binding within the HLA-B*35:02 antigen binding cleft, and may 
potentially alter the profile of peptides that normally bind to HLA-B*35:02, as has been 
shown with abacavir binding to HLA-B*57:01 (30). Crystal structures demonstrate that 
abacavir forms contact with specific peptides and HLA-B*57:01. Several contacts between 
the drug, peptide and HLA are mediated by ordered water molecules. Molecular docking of 
minocycline to HLA-B*35:02 is limited by lack of knowledge regarding peptides that bind 
in the presence of the drug. Moreover, it is not possible to accurately predict the locations of 
ordered water molecules in a model of HLA-B*35:02. Future studies characterizing peptides 
bound to HLA-B*35:02 are expected to elucidate functional drug interaction mechanisms 
for this (and other) HLA-DILI associations.
No significant difference in clinical presentation or outcome based upon HLA-B* 35:02 
genotype was observed except for lower total bilirubin levels and R-values (Table 1) (see 
supplemental Table 1 for additional information). This may be due to the limited number of 
cases enrolled (25), with only 4 HLA-B*35:02 carriers among this set, or a true lack of 
difference in presentation or outcomes related to HLA-B*35:02 carrier status. A larger 
number of minocycline DILI cases used for genetic validation could also help determine if 
the HLA-B*35:02 carriers have any unique clinical or laboratory features compared to non-
carriers with minocycline DILI. Nonetheless, our data are consistent with other GWAS 
studies in DILI subjects demonstrating an association of HLA region with DILI 
susceptibility (31-33). Many of these are in the HLA Class I genes (specifically, HLA-A or 
HLA-B), though the HLA Class II genes have also been implicated. These studies suggest a 
role for adaptive immunity in DILI pathogenesis.
Many of our patients had autoimmune like features at presentation. Furthermore, available 
liver biopsies demonstrated some features of AIH in some patients (Table 2). Up to 50% of 
patients were treated with steroids and most did well. Steroids were successfully tapered off 
in most patients. Although there were no liver transplants or deaths, 24% evolved into 
chronic DILI which is higher than our prior report (9). This may in part be due to prolonged 
use of the drug in these patients. Furthermore, most of these patients did not get routine labs 
drawn prior to use. Lastly, a substantial delay between first evidence of DILI (abnormal labs) 
and drug cessation was observed with 11 subjects discontinuing the drug after a median of 
38 days after DILI onset. Prior studies have suggested that continued suspect drug use is 
associated with more severe DILI and chronicity (34). However, the median duration of 
minocycline use in the 5 DILIN subjects who developed chronic DILI was not significantly 
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longer than the duration of use in the 12 without chronic DILI (252 vs 400 days, p=0.6). 
And the duration of minocycline use after DILI onset was not longer in those with chronic 
vs self-limited DILI (1 day for both groups, p=0.8). Fortunately at month 24 of follow-up, 
none of the 5 chronic DILI patients had evidence of cirrhosis, portal hypertension or liver 
failure and in fact all had normalized their liver biochemistries.
Recent studies have suggested that certain HLA alleles (i.e. HLA-DRB1*0301, HLA-
DRB1*0401) may be associated with susceptibility to autoimmune hepatitis in Caucasians 
(35). When we looked for these specific alleles, there was no over-representation in our 
minocycline cases compared to population controls (Data not shown). However, the lack of 
an association may be due to lack of power owing to the small number of minocycline DILI 
cases.
Given the low incidence of DILI amongst patients receiving minocycline, HLA typing is 
unlikely to help prevent minocycline DILI. However, HLA-B*35:02 may be useful as a 
diagnostic aid in the setting of suspected minocycline DILI especially in distinguishing it 
from sporadic autoimmune hepatitis but confirmatory studies are needed. In addition due to 
the small number of case patients that carry the HLA-B*35:02 allele (n=4), validation of 
these findings in a larger, independent cohort of patients with minocycline DILI is needed.
The mechanism linking minocycline to HLA-B*35:02 is not clear. One possibility is that the 
drug binds directly to the antigen binding cleft similar to abacavir binding to HLA-B*57:01, 
and alters the repertoire of bound 9mer peptide ligands- presumably presenting novel cell 
surface antigens. However, minocycline (molecular weight 493.9 daltons) is larger than 
abacavir (molecular weight 286.3 daltons) and may hinder conventional 9mer peptide ligand 
interactions. That is, minocycline may be presented in the absence of conventional peptides 
(e.g., 9mers). An alternative model is that minocycline metabolites bind HLA, forming 
complexes recognized by CD8+ cytotoxic T-lymphocytes. Another potential mechanism is 
that stressed/damaged hepatocytes exhibit immunogenic peptide/HLA complexes that act as 
neoantigens. It also remains possible that minocycline or a metabolite binds covalently to 
cellular proteins resulting in the presentation of a drug-peptide complex to T-cells via HLA-
B* 35:02, as appears to occur with flucloxacillin in HLA-B * 57:01 carriers (36). Evidence 
for the formation of a reactive intermediate(s) from minocycline but not other tetracyclines 
has been reported previously (37). Our group and others are planning additional in vitro 
experiments in patients with and without the HLA-B * 35:02 allele to follow-up on these 
preliminary studies. Elucidating the mechanism(s) underlying the association between HLA-
B*35:02 and risk for minocycline hepatotoxicity will lead to a greater understanding of the 
pathophysiology of liver injury from minocycline, and perhaps other hepatotoxic drugs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Lay summary
Development of liver injury following prolonged use of minocycline for acne is a rare but 
potentially severe form of drug induced liver injury. Our study demonstrates that 
individuals who are HLA-B *35:02 carriers are at increased risk of developing 
minocycline related liver injury. These results may help doctors more rapidly and 
confidently diagnose affected patients and possibly reduce the risk of liver injury in 
individuals receiving minocycline going forward.
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Figure 1. Manhattan plot showing genome-wide single variant association test results
The -log10(P value) from a logistic regression of each SNP on phenotype is plotted 
according to physical location of the SNPs on each of the 22 autosomes, with SNPs on 
different chromosomes colored with alternating colors. SNPs that exceeded a p-value of 10-5 
threshold are marked in green color.
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Figure 2. LocusZoom plot of association test results in the MHC region
The -log10(P value) from a logistic regression of each SNP as well as HLA-B*35:02 on 
phenotype is plotted according to physical locations in the MHC region. Linkage 
disequilibrium between each of the SNPs and the lead GWAS SNP (rs146765245) is 
indicated by color. Associations with the GWAS SNPs were not genome-wide significant, 
but imputation of HLA types revealed a genome-wide significant association with HLA-
B*35:02. Local recombination rate in this region is also shown with the second Y-axis on the 
right. Several HLA genes with their direction of transcription are marked by arrows on the 
bottom and the locations of SNPs are marked by vertical bars on the top. This plot is 
generated using the web tool LocusZoom at http://locuszoom.sph.umich.edu/locuszoom/.
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Figure 3. Molecular docking of minocycline in the HLA-B*35:02 antigen binding cleft
(a) A ribbon diagram of HLA-B*35:02 showing minocycline with white sticks for carbon, 
blue for nitrogen, red for oxygen, and white for hydrogen. Yellow dashes represent polar 
interactions between minocycline and HLA-B*35:02. (b). Minocycline is shown in the top 
scoring binding orientation predicted by molecular docking using AutoDock Vina. The 
molecular surface of HLA-B*35:02 is showing as violet for carbon, blue for nitrogen, red 
for oxygen, and white for hydrogen.
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Table 2
Liver histopathology in 8 DILIN subjects with minocycline hepatotoxicity
Age (years) Gender
Duration of 
Minocycline use (d)
Days from DILI 
onset to biopsy Findings
17 Male 570 144 Marked chronic hepatitis, eosinophils
18 Female 701 22
Marked chronic hepatitis, plasma cells and eosinophils, bridging 
fibrosis
16 Female 197 101 Moderate chronic hepatitis
55 Female 588 8 Moderate cholestatic chronic hepatitis, plasma cells, eosinophils
17 Female 387 220 Mild chronic hepatitis, plasma cells
31 Female 43 10 Marked acute cholestatic hepatitis, plasma cells, eosinophils
19 Female 74 5 Marked acute hepatitis, plasma cells, early bridging fibrosis
19 Male 384 2 Marked acute cholestatic hepatitis, eosinophils
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